Compare the Global Sales of Blockbuster Drugs Losing Patent in 2014
Jul 18, 2014
Compare the global sales of 2013 and 2012 of the top ten blockbuster drugs which is losing patent this year. Teva Pharmaceutical’s Copaxone is the most affected drugs in terms of sales as the sales of 2013 has increased to 4.328 billions bearing the highest loss. Least affected Drug is AbbVie’s Trilipix which has faced the decrease in sales from 1.098 billions to 303 millions.
Table: Global Sales of Blockbuster Drugs for 2012 and 2013
| Brand Name | Global Sales 2012 USD (b) | Global Sales 2013
DownloadsArticle in PDF USD (b) |
| Copaxone | 3.996 | 4.328 |
| Nexium | 3.994 | 3.872 |
| Micardis/Micardis HCT | 2.217 | 0.97 |
| Sandostatin LAR | 1.512 | 1.589 |
| Exforge/Exforge HCT | 1.352 | 1.456 |
| Nasonex | 1.268 | 1.335 |
| Trilipix | 1.098 | 0.303 |
| Evista | 1.01 | 1.05 |
| Renagel/Renvela | 0.861 | 0.75 |
| Restasis | 0.792 | 0.94 |
Downloads
Article in PDF
